Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962280 | 0.77 | ESR1 (0.43) | MEN1ALDH1A1KMT2ACAPN1 | |
| SCHEMBL27656915 | 0.76 | CAPN1 (0.39) | ALDH1A1CYP3A4MAPK1KMT2ACAPN1 | |
| SCHEMBL19401215 | 0.72 | CAPN1 (0.36) | CYP1A2CYP3A4CYP2D6CAPN1 | |
| SCHEMBL4560927 | 0.72 | CAPN1 (0.44) | MEN1USP2ALDH1A1CYP1A2CYP3A4 | |
| SCHEMBL96457 | 0.71 | TAAR1 (0.52) | TSHRMEN1USP2ALDH1A1CYP1A2 | |
| SCHEMBL2754650 | 0.70 | — | — | |
| SCHEMBL1698031 | 0.69 | TSHR (0.53) | TSHRMEN1USP2ALDH1A1CYP1A2 | |
| SCHEMBL1216706 | 0.69 | TSHR (0.47) | TSHRMEN1USP2ALDH1A1CYP1A2 | |
| SCHEMBL111724 | 0.69 | ALDH1A1 (0.47) | TSHRMEN1USP2ALDH1A1CYP1A2 | |
| SCHEMBL11217036 | 0.69 | MEN1 (0.41) | TSHRMEN1USP2ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003712-A1 | METHOD FOR PREPARING A SITE-SPECIFIC PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE | HANMI HOLDINGS CO., LTD. (KR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003712-A1 | METHOD FOR PREPARING A SITE-SPECIFIC PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE | VIP, LNPEP, DNPEP | TSHR 243/4885MEN1 651/4885USP2 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.